This article describes the development, evaluation, deployment, and scalability of DART-MS, or Direct Analysis in Real Time Mass Spectrometry, and its applicability in the analysis of emerging drugs such as synthetic opioids and cannabinoids, for rapid evidence processing.
Forensic scientists receive over a million requests for seized drug analysis in the United States each year, and the number is steadily climbing. The proliferation of novel psychoactive substances in recent years, including synthetic opioids and cannabinoids, has contributed to these rising numbers. As a result, researchers are searching for improved ways to evaluate their drug samples for more swift evidence processing. Direct Analysis in Real Time Mass Spectrometry (DART-MS) can determine sample composition from solid, liquid, or gaseous compounds nearly instantaneously, and has garnered recognition as a suitable technique for the rapid analysis of emerging drugs. One drawback to the forensic application of DART-MS has been the difficulty associated with data processing and interpretation of complex drug mixtures. This article discusses how a research team from the National Institute of Standards and Technology, supported by the National Institute of Justice, created an automated data evaluation process, developing and releasing a DART-MS mixture interpretation software program that is free, flexible, vendor agnostic, and open-source. The researchers sought to develop a suite of tools to analyze complex DART-MS spectra rapidly and reliably, easily create or amend spectral databases, identify unknown substances, and generate reports using their Data Interpretation Tool software.
Downloads
Similar Publications
- Germ-Line Transformation of Forensically Important Flies
- Criticality of Spray Solvent Choice on the Performance of Next Generation, Spray-Based Ambient Mass Spectrometric Ionization Sources: A Case Study Based on Synthetic Cannabinoid Forensic Evidence
- Superhydrophobic Surface Modification of Polymer Microneedles Enables Fabrication of Multimodal Surface-Enhanced Raman Spectroscopy and Mass Spectrometry Substrates for Synthetic Drug Detection in Blood Plasma